Press release
Myositis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Corbus Pharmaceuticals, Janssen, Pfizer, Abcuro, Orphazyme, ImmunoForge, Merck, JN Biosciences, Bristol-Myers Squibb, Kezar Life Sciences
"Myositis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myositis Therapeutics Market.
The report provides a detailed description of the Myositis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Myositis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Myositis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Myositis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Myositis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Myositis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Myositis Therapeutics Domain:
https://www.delveinsight.com/report-store/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Myositis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Myositis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Myositis Therapeutics Analysis
There are approx. 20+ key companies developing therapies for Myositis. Currently, Corbus Pharmaceuticals is leading the therapeutics market with its Myositis drug candidates in the most advanced stage of clinical development.
Myositis Companies in the Therapeutics Market Include:
• Corbus Pharmaceuticals
• Janssen Research & Development, LLC
• Pfizer
• Abcuro, Inc.
• Orphazyme
• Bristol-Myers Squibb
• Kezar Life Sciences, Inc.
• Horizon Therapeutics
• Paean Biotechnology Inc.
• Alexion Pharmaceuticals
• ImmunoForge
• JN Biosciences
• Merck KGaA
And Many Others
Emerging and Marketed Myositis Therapies Covered in the Report Include:
• Lenabasum: Corbus Pharmaceuticals
• Nipocalimab: Janssen Research & Development, LLC
And Many More
Get an in-depth Assessment of the Emerging Therapies and Myositis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Myositis Current Treatment Patterns
4. Myositis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myositis Late-Stage Products (Phase-III)
7. Myositis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myositis Discontinued Products
13. Myositis Product Profiles
14. Myositis Companies
15. Myositis Drugs
16. Dormant and Discontinued Products
17. Myositis Unmet Needs
18. Myositis Future Perspectives
19. Myositis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/myositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market
Concussions Market
https://www.delveinsight.com/report-store/concussions-market
Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market
Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market
Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market
Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market
Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market
Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myositis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Corbus Pharmaceuticals, Janssen, Pfizer, Abcuro, Orphazyme, ImmunoForge, Merck, JN Biosciences, Bristol-Myers Squibb, Kezar Life Sciences here
News-ID: 3134170 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Myositis
Inflammatory Myositis Market Massive Growth opportunity Ahead
Introduction
Inflammatory myositis is a group of rare autoimmune disorders characterized by chronic inflammation of skeletal muscles, leading to progressive muscle weakness, fatigue, and functional disability. The spectrum includes polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and overlap syndromes. These disorders can also involve other organs, most notably the lungs (interstitial lung disease), skin, heart, and joints, complicating disease management.
Historically, corticosteroids and conventional immunosuppressants have formed…
Idiopathic Inflammatory Myositis Market Growth, Trends, Consumer Demand and Key …
Introduction
Idiopathic Inflammatory Myositis (IIM) is a rare group of autoimmune muscle diseases characterized by chronic inflammation of skeletal muscles, leading to progressive weakness, fatigue, and in severe cases, disability. The group includes dermatomyositis (DM), polymyositis (PM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and antisynthetase syndrome. IIM can also involve systemic complications such as interstitial lung disease (ILD), cardiac dysfunction, and malignancy association, making management highly complex.
Historically, treatment relied…
Inclusion Body Myositis Market: A Guide to Understanding the Process
The global Inclusion Body Myositis (IBM) market is projected to reach approximately USD 231.4 million by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Inclusion Body Myositis Market Overview
The Inclusion Body Myositis market is growing steadily due to increasing recognition and diagnosis of this rare neuromuscular disorder. Advances in therapeutic research focusing on inflammation and muscle degeneration are driving the development of targeted treatments. Rising patient awareness and…
Myositis Clinical Trials, Pipeline Insights, and Companies 2024
DelveInsight's, "Myositis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Myositis pipeline landscape. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances in Myositis Treatment…
Global Necrotizing Autoimmune Myositis Market - Opportunities & Forecasts, 2020- …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global necrotizing autoimmune myositis market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
Inclusion Body Myositis (IBM) - Pipeline Review And Industry Insight Report 2017
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and…
